CRA experts advised two parties during both the CMA’s investigation and CAT Appeals, assessing the economic evidence and providing expert testimony on what prices could be considered excessive (or, to the contrary, consistent with competitive outcomes) in the UK market for Liothyronine tablets.
CRA strengthens its Antitrust & Competition Economics Practice
“We are pleased to welcome Nate to CRA’s Antitrust & Competition Economics Practice,” said Paul Maleh, President and Chief Executive Officer of Charles River...